An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors.

Kirsty TaylorHelen Loo YauAnkur ChakravarthyBen WangShu Yi ShenIlias EttayebiCharles A IshakPhilippe L BedardAlbiruni Abdul RazakAaron R HansenAnna SpreaficoDave CesconMarcus O ButlerAmit M OzaStephanie LheureuxNeda StjepanovicBrendan Van AsSarah Boross-HarmerLisa WangTrevor J PughPamela S OhashiLillian L SiuDaniel D De Carvalho

Published in: Journal for immunotherapy of cancer (2021)

NCT02811497.

Keyphrases

phase ii
clinical trial
open label
phase iii
randomized controlled trial
placebo controlled